Table IV. Characteristics of responders and non-responders for eligible patients *.
| Responders (CR + CRp) | Non-responders | |||
|---|---|---|---|---|
| N | % | N | % | |
| Total | 23 | 47% | 25 | 51% |
| Gender | ||||
| Male | 14 | 61% | 12 | 48% |
| Female | 9 | 39% | 13 | 52% |
| Patients in first relapse | 22 | 96% | 22 | 88% |
| Patient refractory to induction | 1 | 4% | 3 | 12% |
| Patients with prior hematopoietic stem cell transplant | 2 | 9% | 2 | 8% |
| Cytogenetics (N=40) | ||||
| Normal | 4 | 20% | 4 | 20% |
| Inv(16)/t(16;16) | 6 | 30% | 1 | 5% |
| t(8;21) | 2 | 10% | 2 | 10% |
| Monosomy 7 | 1 | 5% | 0 | 0% |
| Del7q | 0 | 0% | 1 | 5% |
| Del5q | 0 | 0% | 1 | 5% |
| 11q23 | 2 | 10% | 2 | 10% |
| t(6;9) | 1 | 5% | 0 | |
| +8 | 0 | 0% | 4 | 20% |
| Other | 4 | 20% | 5 | 25% |
| Age (y) at study entry (median, range) | 14.7 | 1.4 - 21.5 | 9.0 | 1.7 – 23.0 |
| WBC (× 103/μl) (median, range) | 2.7 | 1.1 - 129.6 | 4.2 | 0.5 - 1400 |
| Length of CR1 in days (median, range) | 374.5 | 42 – 2212 | 258 | 35 - 1066 |
| Received HSCT in follow-up | 21 | 91% | 12 | 48% |
| Number of received courses to best | ||||
| 1 cycle | 12 | 52% | 11 | 44% |
| 2 cycles | 11 | 48% | 14 | 56% |
*
One patient not evaluable for response because therapy was withdrawn before response assessment
CR = Complete Response
CRp = Complete Response with partial recovery of platelet count
CR1 - First remission
HSCT - Hematopoietic Stem Cell Transplant